Home Page Overall Ranking ROE Ranking P/E Ranking Dividend Yield Capitalization Our eBook Our Book Contact










Isin CA91911K1021
Ticker VRX
Company VALEANT PHARMACEUTICALS INTERNATIONAL
Currency $
Price
Aware Investor Index (AII) 0.0000
Recommendation STRONG SELL
P/E 239.46
ROE 1.20 %
Capitalization 15,616,795,000 $
Dividend Yield 0.00 %
P/S 1.89
AII Position 776
P/E Position 766
ROE Position 779
Capitalization Position 415
Dividend Yield Position 629
Sales 8,263,500,000 $
10-Year Average Earnings 65,217,000 $
Shares Outstanding 341,500,000
Equity 5,434,500,000 $
Dividend per Share 0 $
Industry Pharmaceutical
Country Canada
VALEANT PHARMACEUTICALS INTERNATIONAL Investor Relations Web Site http://ir.valeant.com







Sales:

YEAR MONTH AMOUNT
2014 12 8,263,500,000.00 $
2013 12 5,769,605,000.00 $

Earnings:

YEAR MONTH AMOUNT
2014 12 913,500,000.00 $
2013 12 -866,142,000.00 $
2012 12 -116,025,000.00 $
2011 12 159,559,000.00 $
2010 12 -208,193,000.00 $
2009 12 176,455,000.00 $
2008 12 199,904,000.00 $
2007 12 103,541,000.00 $
2006 12 228,939,000.00 $
2005 12 60,632,000.00 $

Equity:

YEAR MONTH AMOUNT
2014 12 5,434,500,000.00 $
2013 12 5,233,322,000.00 $
2012 12 3,717,398,000.00 $

Shares Outstanding:

YEAR MONTH AMOUNT
2014 12 341,500,000
2013 12 320,996,000
2012 12 303,861,000

 












Bloomberg News for VALEANT PHARMACEUTICALS INTERNATIONAL:

Jan 3, 2011
U.S. Stock Options With Biggest Changes in Implied Volatility
1368 SSO PROSHARES U SSO US 01/22/11 C40 16.9 53.7 9.27 14.4 517 VRX VALEANT PHA VRX US 01/22/11 C26 16.8 47.4 3.05 -7.6 1000 CSCO CISCO SYSTE CSCO US 01/22/11...
Aug 4, 2011
Iridian Asset Mgmt Holdings in 2nd Quarter: 13F Alert
(USD $) Position In Position Valeant Pharmaceuticals Inte VRX US 295,603,506 5,689,059 -1,052,171 Wyndham Worldwide Corp WYN US 274,946...
Apr 21, 2011
ARC Resources, Celestica, Silver Wheaton: Canada Equity Preview
Steven Butler, an analyst at Canaccord Financial Inc. Valeant Pharmaceuticals International Inc. (VRX CN): Canada’s largest drugmaker said it is prepared to “modestly” raise its bid for Cephalon Inc...
Feb 15, 2011
ValueAct Holdings Largest Holdings in 4th Qtr: 13F Alert
(USD $) Position In Position Valeant Pharmaceuticals Inte VRX US 762,695,599 26,959,901 Sara Lee Corp SLE US 611,428...
Feb 14, 2011
Brahman Capital Corp Largest Holdings in 4th Quarter: 13F Alert
Technologies Holding ST US 70,728,842 2,349,015 2,349,015 Valeant Pharmaceuticals Inte VRX US 65,248,056 2,306,400 -254,700 Xerox Corp XRX US 57,273...
Jan 6, 2011
U.S. Stock Options With Biggest Changes in Implied Volatility
1500 CVE CENOVUS ENE CVE US 03/19/11 C22.5 17.3 55.9 10.30 -5.5 500 VRX VALEANT PHA VRX US 01/22/11 C32 17.1 38.9 3.30 407.7 1291 CSX CSX CORP CSX US 01/22/11...
Dec 1, 2003
A New Way To Fight Hepatitis C
better at bypassing the blood cells and going straight to the liver. Valeant Pharmaceuticals (VRX), formerly ICN Pharma-ceuticals (ICN), developed both drugs. And it announced in early November...
Oct 2, 2008
North and South American Stock Rating Changes, New Coverage
-------------------------------------------------------------------------------- Valeant Pharmaceuticals Inte (VRX US) Matrix/Lighthouse Analyst Recommendation Action Target Team Coverage...
Feb 27, 2006
In India, Selling Generics Used To Be So Easy
Jersey, and bought an Ohio factory from California-based Valeant Pharmaceuticals International (VRX ). In December, Bombay's Glenmark Pharmaceuticals announced a deal with InvaGen Pharmaceuticals...
Nov 10, 2011
Zweig Dimenna Partners Holdings in 3rd Quarter: 13F Alert
Freeport-McMoRan Copper FCX US -21,681,938 173,360 -336,295 Valeant Pharmaceuticals Inte VRX US -20,560,233 124,345 -360,180 Williams Cos Inc WMB US -17,574...


Google News for VALEANT PHARMACEUTICALS INTERNATIONAL:

PR Newswire (press release) - 1 day ago
Valeant Receives FDA Confirmation Of Voluntary Action Indicated ...
LAVAL, Quebec, Aug. 16, 2017 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) ("Valeant" or the ...
MarketWatch
Valeant: There's No Denying It
Valeant Pharmaceuticals (VRX) had a great quarter if you account for the divestitures. ... Bausch & Lomb/International grew by 6% organically.
Market Exclusive
Valeant Pharmaceuticals International (VRX) Q2 2017 Results ...
Good morning, everyone, and welcome to Valeant Pharmaceuticals second quarter 2017 financial results conference call. Participating on ...
Tampa Bay Business Journal
Valeant Pharmaceuticals: Cramer's Top Takeaways
Valeant Pharmaceuticals: Cramer's Top Takeaways ... down with Joe Papa, chairman and CEO of Valeant Pharmaceuticals International (VRX) ...
Seeking Alpha - 10 Aug 2017
Valeant: Earnings Expose Problem
Valeant Pharmaceuticals (VRX) is unable to generate enough organic growth to make up for patent LOEs and divestitures in its portfolio.
Nasdaq
Valeant Pharmaceuticals International Inc (VRX), AT&T Inc (T ...
Shares of Valeant Pharmaceuticals International Inc (VRX) are moving on volatility today 1.34% or $0.19 from the open. The NYSE listed ...
PR Newswire (press release)
Valeant Reports Received FDA Confirmation Of VAI Inspection ...
Related Articles (VRX). Watch These 4 Huge Put Purchases In Monday Trade · Watch These 4 Huge Call Purchases In Monday Trade.
Barron's
Valeant Pharmaceuticals Receives Complete Response Letter from ...
LAVAL, Quebec, Aug. 7, 2017 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) today announced it has ...
Seeking Alpha - 8 Aug 2017
Valeant: Much More Upside Remains, Despite Messy Quarter
Valeant (VRX) reported Q2 earnings on Tuesday morning. ... Most of the growth came from the international business, especially China. This is ...
Barron's
Valeant Pharmaceuticals International, Inc. (VRX) Given Average ...
Valeant Pharmaceuticals International logo Valeant Pharmaceuticals International, Inc. (NYSE:VRX) (TSE:VRX) has been given a consensus ...


Back